Latest news with #USPTO
Khaleej Times
an hour ago
- Business
- Khaleej Times
UAE, US sign statement to accelerate patent granting procedures
UAE and the US signed a statement that seeks to accelerate patent granting procedures in the UAE. This was signed on the sidelines of the 66th Assemblies of the Member States of the World Intellectual Property Organisation (WIPO) in Geneva, by the Ministry of Economy and Tourism and the United States Patent and Trademark Office (USPTO). The Joint Statement of Intent is aimed at launching a bilateral cooperation programme which provides collaborative mechanisms to recognise positive examination results issued by the USPTO for corresponding Emirati patent applications. This will be implemented in accordance with applicable national laws. The focus is on industrial property rights and the development of patent registration procedures that provide flexible and efficient services which support an innovation-driven and entrepreneurial environment. This cooperation reflects the UAE's commitment to enhancing the competitiveness of its intellectual property ecosystem by adopting international best practices, stressed Abdullah bin Touq Al Marri, Minister of Economy and Tourism. He also highlighted that the partnership with the US side represents a new push to accelerate patent issuance by strengthening international cooperation and adopting advanced operational models.
Al Etihad
an hour ago
- Business
- Al Etihad
UAE, USA sign joint statement of intent to accelerate patent grant procedures
20 July 2025 13:16 GENEVA (WAM)The United Arab Emirates and the United States of America signed a joint statement of intent aimed at launching a bilateral cooperation programme to accelerate patent granting procedures in the signing took place on the sidelines of the 66th Assemblies of the Member States of the World Intellectual Property Organisation (WIPO) in to the joint statement, signed by the UAE Ministry of Economy and Tourism and the United States Patent and Trademark Office (USPTO), the programme provides collaborative mechanisms to recognise positive examination results issued by the USPTO for corresponding Emirati patent applications. The procedure will be implemented in accordance with applicable national bin Touq Al Marri, UAE Minister of Economy and Tourism, emphasised that the cooperation reflects the UAE's commitment to enhancing the competitiveness of its intellectual property ecosystem by adopting international best particular, the agreement aims to strengthen industrial property rights, and enhance patent registration procedures to provide flexible and efficient services that support an innovation-driven and entrepreneurial environment. The effort is designed to reinforce the UAE's position as a regional hub for intellectual property rights Marri also highlighted that the partnership represents a push to accelerate patents by strengthening international cooperation and adopting advanced operational models. The measures aim to ensure faster and more efficient protection for inventors and entrepreneurs, creating an encouraging environment for innovation and investment in knowledge- and technology-based sectors, and enhancing the UAE's readiness for a creativity-driven economic future. The cooperation is part of the Ministry's broader efforts to develop the industrial property system, streamline procedures, and offer high-quality, flexible services to innovators in support of the country's business environment.
National Post
3 days ago
- Business
- National Post
Cabbacis Granted U.S. Patent for Vaporizer Pods
Article content NIAGARA FALLS, N.Y. — Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on harm-reduction products being developed under the iBlend™ brand name, today announced that the United States Patent and Trademark Office has issued a patent to Cabbacis for vaporizer pods for oral electronic vaporizers. Article content Article content U.S. Patent No. 12,349,724, which expires on July 27, 2038, includes ten claims on pods for electronic vaporizers. The claims cover vaporizer pods comprising blends of at least 5 mg of conventional-nicotine reconstituted tobacco and at least 5 mg of hemp, and separately, at least 5 mg of reduced-nicotine reconstituted tobacco and at least 5 mg of hemp. Reconstituted tobacco is typically used in closed-end electronic vaporizer pods. Commercial examples of popular, closed-end electronic vaporizers – also known as heat-not-burn products – include IQOS®, Ploom® and glo®. Article content Vaporizer pods covered under the 724 patent that contain conventional-nicotine tobacco and hemp will provide consumers with pleasant and differentiated taste and sensory characteristics, as compared to the above vaporizer brands that contain conventional-nicotine tobacco without any hemp. Article content Cabbacis owns two other previously-issued U.S. patents on vaporizer pods containing tobacco and hemp: 10,777,091 and 10,973,255 along with various international vaporizer pod patents. Article content The Company's patented, reduced-nicotine, iBlend™ vaporizer pods and patented, reduced-nicotine, iBlend™ cigarettes in development are to assist vapers or smokers of conventional tobacco products to vape or smoke less or transition to less harmful tobacco or nicotine products. iBlend™ reduced-nicotine cigarettes contain approximately 95 percent less nicotine than conventional cigarette brands. The Company's products in development are patented in many of the largest tobacco markets across the globe including the United States, China, Europe, Brazil and Japan. Article content Joseph Pandolfino, Chief Executive Officer of Cabbacis, commented, 'We are thrilled to announce this new patent for vaporizer pods, further fortifying our already robust intellectual property position. This patent, when taken in tandem with our existing patents, comprehensively cover, across more than 30 countries, any ratio of reduced-nicotine tobacco and hemp blended together in cigarettes and/or any ratio of conventional-nicotine tobacco and hemp or reduced-nicotine tobacco and hemp blended together in vaporizer products.' Article content About Cabbacis Article content Cabbacis (OTCQB: CABI) is committed to commercializing groundbreaking tobacco harm-reduction products in the global tobacco market for the world's one billion smokers with its flagship iBlend™ reduced-nicotine cigarettes and vaporizer pods in development. These patent protected products combine reduced-nicotine tobacco with non-intoxicating hemp to assist in vaping or smoking less, transitioning to less harmful tobacco products, and/or increasing quit attempts. Both types of products in development are predominately tobacco and include hemp. In a recent clinical trial, the Company's patented, reduced-nicotine iBlend™ cigarettes were highly rated for satisfaction on the standardized mCEQ questionnaire and significantly reduced cravings for usual brand cigarettes. The Company also plans to commercialize reduced-nicotine tobacco cigarettes and little cigars without hemp and vaporizer pods with conventional-nicotine tobacco and hemp. Article content The worldwide patent portfolio of Cabbacis LLC includes 35 issued patents and various pending patent applications across the United States, Europe, China, India, Japan, Indonesia, Russia, South Korea, Canada, Australia, New Zealand, Mexico, Brazil and other countries – where approximately two-thirds of the world's smokers reside. Cabbacis holds 7 U.S. patents. Cabbacis LLC is a wholly-owned subsidiary of Cabbacis Inc. Article content Reduced-nicotine cigarettes without hemp that contain about 95 percent less nicotine than conventional cigarettes have been evaluated in dozens of independent studies. Results demonstrate, as reviewed in Donny and White 2022 (Int J Drug Policy 99:103436), that subjects smoked fewer cigarettes per day, reduced their nicotine dependence and exposure, doubled their quit attempts, and/or increased their number of smoke-free days. Article content Cautionary Note Regarding Forward-Looking Statements Article content This press release includes forward-looking statements within the meaning of the federal securities law. All statements other than statements of historical or current facts made in this document are forward-looking. We identify forward-looking statements in this document by using words or phrases such as 'anticipate,' 'believe,' 'consider,' 'continue,' 'could,' 'estimate,' 'expect,' 'foresee,' 'intend,' 'likely,' 'may,' 'objective,' 'potential,' 'plan,' 'predict,' 'project,' 'seek,' 'should,' 'will' and similar words or phrases and their negatives. Forward-looking statements reflect our current expectations and are inherently uncertain. Actual outcomes or results could differ materially for a variety of reasons. Factors that could cause actual results to differ materially are described in 'Risk Factors' in our Regulation A Offering Circular filed with the SEC and in our Annual Report on Form 1-K for the period ended December 31, 2024 filed with the SEC. We undertake no responsibility to publicly update or revise any forward-looking statement except as required by applicable law. Article content This press release does not constitute an offer to sell or the solicitation of an offer to buy the Company's securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of that state or jurisdiction. Article content Article content Article content Article content Article content Contacts Article content Investor Relations Contact: Article content Article content Lucas A. Zimmerman Article content Article content Managing Director Article content Article content Article content
Associated Press
11-07-2025
- Automotive
- Associated Press
United States Patent and Trademark Office Grants Patent Allowance for Polypave Court Shield
This achievement marks a major milestone in the development and commercialization of this proprietary surface technology. ZEBULON, NC, UNITED STATES, July 11, 2025 / / -- North State Resurfacing and Polypave Court Shield, LLC. are proud to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the patent application covering Polypave Court Shield. Polypave is an innovative crack-prevention system for newly paved asphalt athletic courts. This achievement marks a major milestone in the development and commercialization of this proprietary surface technology. About the Polypave Court Shield System Polypave Court Shield is a proprietary crack-prevention system developed specifically for newly paved asphalt athletic courts, including tennis courts, pickleball courts, and basketball courts, and multi-use courts. Designed to proactively mitigate surface cracking, the system addresses one of the most common and costly problems in court construction: early-stage asphalt shrinkage and stress cracking. Engineered for Long-Term Performance Unlike traditional sport court repair methods that treat cracks after they appear, Polypave Court Shield is applied during the initial construction phase to help prevent cracking before it begins. By forming a flexible, protective layer between the asphalt surface and acrylic coatings, the system allows the pavement to continue curing beneath while shielding the finished court surface from reflective cracks. Its application is fast, effective, and minimally invasive—making it an ideal solution for court builders seeking to extend surface life and reduce future maintenance. Patent Allowance Validates Polypave's Future as a Trusted Crack-Prevention System USPTO's issuance of a Notice of Allowance formally recognizes the originality and value of the Polypave Court Shield system. This milestone confirms the product's distinct approach to surface preservation and supports its entry into broader commercial use. Scaling Innovation for Widespread Distribution With the patent allowance in place, Polypave Court Shield is poised to enter the market on a national scale. The upcoming rollout will focus on making the system accessible to contractors and athletic facility managers across North America. For court owners, this means earlier access to a proven solution that proactively prevents cracking, extends surface lifespan, and reduces long-term maintenance costs. As distribution expands, more new asphalt courts will have the opportunity to incorporate this protective layer from the start—offering a smarter investment in performance, aesthetics, and durability. For athletes playing at these facilities, the result is a smoother, more consistent playing surface that enhances safety, performance, and overall experience. By addressing problems before they appear, Polypave Court Shield supports long-term durability and player satisfaction—making it a smart upgrade for any new athletic court project. For inquiries, partnership opportunities, or distribution details, please contact Mike Alford, President of North State Resurfacing and engineer of the Polypave Court Shield system, by calling: (252) 955-7439 or emailing: [email protected]. About North State Resurfacing and Polypave Court Shield, LLC. North State Resurfacing is a leading athletic court construction and resurfacing company based in Zebulon, North Carolina. With decades of industry experience and a focus on quality craftsmanship, the company has built a reputation for innovation in sport surface design. Polypave Court Shield, LLC. is a separate entity focused on the development and distribution of the Polypave Court Shield system. Its mission is to improve the long-term performance of asphalt athletic courts through patented, preventative technology. Mike Alford Polypave Court Shield, LLC +1 252-955-7439 [email protected] Visit us on social media: Other Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Yahoo
10-07-2025
- Business
- Yahoo
Geneticure Inc. Granted New U.S. Patent for Genetic Test to Predict Response in Renal Denervation for Hypertension
The patent supports the Company's broader mission to eliminate trial-and-error in treating hypertension (High Blood Pressure) with medications and medical devices. ROCHESTER, Minn., July 10, 2025--(BUSINESS WIRE)--Geneticure Inc., a leader in precision medicine for cardiovascular disease, announced today that the United States Patent and Trademark Office has granted U.S. Patent No. 12,351,873, for a Genetic-Based Weighted Algorithm Model for Predicting Response to Renal Denervation. This groundbreaking patent protects Geneticure's proprietary method of using a patient's genetic profile to predict their likelihood of benefiting from renal denervation — a minimally invasive procedure used to treat hypertension. "Renal denervation has demonstrated the ability to reduce blood pressure in certain patients, with other's experiencing no change or an increase in blood pressure post-denervation." said Scott Snyder, CEO of Geneticure. "Prior to Geneticure's research, a reliable method of predicting the response had not yet emerged and regardless of the denervation method, the changes in blood pressure have been variable across patient populations. Our technology has proven to identify the individuals most likely to respond, enabling more targeted use of this emerging therapy with increased prospects for adoption and payer coverage." The patented method leverages specific genetic markers combined with a proprietary weighted algorithm to determine responsiveness to renal denervation, enabling physicians to make informed treatment decisions beyond traditional risk-factor assessments. This newly issued patent expands Geneticure's growing intellectual property portfolio in the field of pharmacogenomics and device response prediction, further positioning the company at the forefront of personalized hypertension management. More on Geneticure for Renal Denervation: About Geneticure Geneticure Inc. is an Integrated Computational Genomic medicine company focused on eliminating the trial-and-error approach to treating chronic diseases. By integrating a patient's genetic information with physiologic insights, Geneticure provides physicians with actionable tools to optimize therapy selection and improve outcomes. The company's flagship offerings include genetic tests that predict response to common hypertension medications and now, response to renal denervation. View source version on Contacts Media Contact: Scott SnyderChief Executive OfficerGeneticure
